Key result
Review of MS therapies lacks quantitative results on the link between comorbidities and treatment effectiveness.
Why the study?
Differential treatment effects by individual characteristics impact clinical decisions, yet whether comorbidity status modifies treatment effects in multiple sclerosis is not commonly evaluated.
Does comorbidity status modify the treatment effectiveness of disease-modifying therapies in patients with multiple sclerosis?
Does comorbidity status modify the treatment effectiveness of disease-modifying therapies in patients with multiple sclerosis?
This study investigates whether comorbidity status modifies the effectiveness of disease-modifying therapies in multiple sclerosis.
Comorbidity-stratified analyses in MS RCTs may refine DMT selection; extends trial evidence to real-world comorbid populations.
The presence of differential treatment effect according to an individual's characteristics has important implications in clinical decision-making. Yet, whether comorbidity status modifies the effect of treatment in chronic conditions such as multiple sclerosis (MS) is not commonly evaluated. The objective of this study was to examine the association between comorbidities and treatment effectiveness of MS disease-modifying therapies in randomized clinical trials.
No takes yet. Share an insight, caveat, or question.
Salter et al. (2026) conducted a review in Multiple sclerosis. Disease-modifying therapies was evaluated on Treatment effectiveness. The abstract outlines an objective to examine the association between comorbidities and treatment effectiveness of MS disease-modifying therapies, but reports no quantitative results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: